Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.
Risedronate for Prevention of Osteoporosis After Spinal Cord Injury
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Hamilton Health Sciences, Chedoke Site
-
Toronto, Ontario, Canada, M4G 3V9
- Toronto Rehab, Lyndhurst Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Traumatic spinal cord injury less than 100 days.
- Must be able to swallow tablets and sit upright.
Exclusion Criteria:
- Bilateral knee flexion contractures.
- Pregnant, lactating or post-menopausal females.
- Paget's disease, osteomalacia, steroid induced bone loss, untreated thyroid disease, iritis, uveitis, pancreatitis, gastritis, peptic ulcer or cholecystitis.
- Treatment in the last year with calcitonin, fluoride or anabolic steroid.
- Concurrent treatment with prednisone.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Change in bone mineral density of the distal femur and proximal tibia between baseline, 12-months and 24-months.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Frequency and severity of adverse events.
|
|
Quality of life.
|
|
Change in bone mineral density of the total body, spine and femoral neck between baseline, 12-months and 24-months.
|
|
Change in biochemical markers of bone turnover between baseline, 12-months and 24-months.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: B. Cathy Craven, MD, FRCPC, Toronto Rehabilitation Institute
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Musculoskeletal Diseases
- Trauma, Nervous System
- Spinal Cord Diseases
- Bone Diseases
- Bone Diseases, Metabolic
- Wounds and Injuries
- Osteoporosis
- Spinal Cord Injuries
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Risedronic Acid
Other Study ID Numbers
Other Study ID Numbers
- TRI REB #02-040
- ONRO-79
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.